SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Catalytica Energy Systems, Inc. (CESI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Erik T who wrote (1402)10/6/1999 1:20:00 PM
From: Biomaven  Read Replies (2) of 1514
 
I wonder if Glaxo's announcement today of a manufacturing retrenchment might slow their taking some of their CTAL-manufactured products back in-house. Sounds like they are cutting back half in the UK, half elsewhere, with emphasis on formulation facilities.

October 6, 1999

----------------------------------------------------

Glaxo Unveils Manufacturing Overhaul,
Shrinking Payroll by 5.7% in Four Years
By STEPHEN D. MOORE
Staff Reporter of THE WALL STREET JOURNAL

Glaxo Wellcome PLC unveiled a long-awaited overhaul of its global manufacturing operations, designed to reduce annual operating costs by 7% and shrink the British drug maker's world-wide payroll by 5.7% over the next four years.

<snip>

The manufacturing overhaul will target so-called formulation plants, where medicines are mixed, pressed into tablets or capsules and packaged. About half the projected job cuts will be in the U.K. The company said it plans to phase out a plant in Dartford, Kent, by 2003, cutting 1,500 jobs.

<snip>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News